CD274 and non-small cell lung carcinoma: Envafolimab, the world’s first subcutaneous PD-L1 inhibitor, has been approved for the second-line treatment of advanced MSI-H/dMMR colorectal cancer, stomach cancer, and other solid tumors (including NSCLC) by NMPA in 2021.